Incyte

ABOUT

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients and make a difference in healthcare. Incyte’s unique expertise in medicinal chemistry and biology has enabled us to establish a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity, including 24 clinical compounds in development.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. We have more than 2,500 employees, including more than 1,000 world-class scientists, who are committed to discovering first-in-class medicines for patients who previously had limited treatment options.

For more information about Incyte, please visit us at www.Incyte.com. Follow Incyte on X, LinkedIn, Facebook and Instagram.

1801 Augustine Cut-off, Wilmington, DE 19803

Visit website

NEWS

BioCapital

When Failure Feeds on Itself

Sometimes it feels like biotech’s successes and failures come in waves—even when it involves entirely unrelated clinical programs. This past month has had many in industry feeling like they’re underwater.

April 24, 2018

3 min read

Karl Thiel

Black clock with Review time, three-dimensional rendering, 3D illustration

Policy

Eli Lilly and Incyte Shares Drop as FDA Raises Concerns about Arthritis Drug

Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.

April 19, 2018

2 min read

Mark Terry

Drug Development

Roche Halts Colorectal Cancer Trial Recruitment After 4 Patient Deaths

Roche announced it had temporarily halted recruiting patients to its Phase II MODUL clinical trial for metastatic colorectal cancer after four patient deaths. The patients were receiving Tecentriq (atezolizumab) in combination with Exelixis’ MEK inhibitor Cotellic (cobimetinib).

April 11, 2018

3 min read

Mark Terry

Drug Development

Incyte Nosedives: Drug Combo Fails Melanoma Phase III Trial

Shares of Incyte Corporation are down more than 20 percent this morning after the company revealed that pairing is IDO1 drug in combination with Merck’s Keytruda failed to meet endpoints in a Phase III melanoma trial.

April 6, 2018

2 min read

Alex Keown

Biotech Bay

Tempest Therapeutics Leaps into IDO Development with $70M

Versant Ventures spinoff company Tempest Therapeutics secured $70 million in a Series B funding to advance the company’s immunotherapy pipeline.

March 28, 2018

2 min read

Alex Keown

FDA

Eli Lilly Gets Another Shot at FDA Approval for RA Drug

On April 23, the FDA’s arthritis advisory committee will take another look at Eli Lilly’s re-submission for their moderate-to-severe rheumatoid arthritis drug.

March 15, 2018

2 min read

Mark Terry

Deals

5 Biotechs Drawing Buyout Buzz in 2018

Here are five possible acquisition targets to keep an eye on.

January 24, 2018

4 min read

Mark Terry

Biotech Bay

3 Hot Cancer Immunotherapies Waiting To Blast Off in 2018

Immuno-oncology therapeutics have revolutionized certain types of cancer treatments, and they are, in many ways, as close to miracle cures as we’ve seen in decades.

December 22, 2017

2 min read

Mark Terry